Claros Diagnostics Inc.
This article was originally published in Start Up
Executive Summary
A point-of-care diagnostic instrument that had the advantages of a test strip device in terms of ease-of-use and rapid results along with ELISA-like capabilities for major diseases would make diagnosis routine within the course of a patient visit and would revolutionize diagnostic practices. Claros Diagnostics has developed just such a device which it hopes to sell to doctors' offices, initially for urological applications, beginning in 2009.
You may also be interested in...
Start-Up Previews (02/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.
Start-Up Previews (02/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.
Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse
Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.